Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options
Standard
Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. / Ramasamy, Karthik; Gay, Francesca; Weisel, Katja; Zweegman, Sonja; Mateos, Maria Victoria; Richardson, Paul.
in: Blood reviews, Jahrgang 49, 09.2021, S. 100808.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options
AU - Ramasamy, Karthik
AU - Gay, Francesca
AU - Weisel, Katja
AU - Zweegman, Sonja
AU - Mateos, Maria Victoria
AU - Richardson, Paul
N1 - Copyright © 2021 Elsevier Ltd. All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - Despite the recent introduction of new therapies for multiple myeloma (MM), it remains an incurable disease. As MM progresses, patients experience cycles of relapse and remission, with remission periods becoming increasingly shorter as the disease becomes less treatment-sensitive. The treatment of relapsed refractory MM (RRMM) remains a significant clinical challenge. Patients with RRMM are a highly heterogeneous group and choosing the most appropriate treatment requires careful consideration. Furthermore, the number of treatment options for MM is continually growing with no definitive consensus to guide treating clinicians. The emergence of second-generation proteasome inhibitors (e.g., carfilzomib and ixazomib), immunomodulatory drugs (e.g., pomalidomide) and monoclonal antibodies (e.g., isatuximab) has expanded an already complex treatment landscape. This review provides a clear summary of the available treatments for MM and discusses how to tailor treatments to individual patients' needs. Novel treatments currently under clinical development, including venetoclax, melflufen and CAR T-cell therapies, are also discussed.
AB - Despite the recent introduction of new therapies for multiple myeloma (MM), it remains an incurable disease. As MM progresses, patients experience cycles of relapse and remission, with remission periods becoming increasingly shorter as the disease becomes less treatment-sensitive. The treatment of relapsed refractory MM (RRMM) remains a significant clinical challenge. Patients with RRMM are a highly heterogeneous group and choosing the most appropriate treatment requires careful consideration. Furthermore, the number of treatment options for MM is continually growing with no definitive consensus to guide treating clinicians. The emergence of second-generation proteasome inhibitors (e.g., carfilzomib and ixazomib), immunomodulatory drugs (e.g., pomalidomide) and monoclonal antibodies (e.g., isatuximab) has expanded an already complex treatment landscape. This review provides a clear summary of the available treatments for MM and discusses how to tailor treatments to individual patients' needs. Novel treatments currently under clinical development, including venetoclax, melflufen and CAR T-cell therapies, are also discussed.
U2 - 10.1016/j.blre.2021.100808
DO - 10.1016/j.blre.2021.100808
M3 - SCORING: Review article
C2 - 33863601
VL - 49
SP - 100808
JO - BLOOD REV
JF - BLOOD REV
SN - 0268-960X
ER -